Pfizer Inc. PFE announced that the FDA has approved its cancer drug Braftovi (encorafenib) in combination with Eli Lilly’s LLY EGFR antagonist, Erbitux (cetuximab), for the treatment of BRAFV600E-mutant metastatic colorectal cancer in patients having received prior therapy.
Following this nod, the Braftovi combo became the first and the only FDA-approved targeted regimen for the said indication. The FDA approval was based on data from the phase III BEACON CRC study, the only analysis specifically designed to evaluate the given patient population.
Data from the study showed that Braftovi plus Erbitux demonstrated a median overall survival (OS) of 8.4 months compared to 5.4 months for the control arm (irinotecan with Erbitux or Folfiri with Erbitux).
Moreover, the Braftovi combo showed an objective response rate (ORR) of 20% versus 2% for control arm while the median progression-free survival was 4.2 months in the Braftovi combo arm compared to 1.5 months in the control arm.
Notably, in December 2019, the FDA accepted and granted a priority review to the supplemental new drug application (sNDA) for Braftovi plus Erbitux to address the above indication
A similar label expansion application for Braftovi is under review in Europe. The application was filed by Array BioPharma’s European partner Pierre Fabre.
Shares of Pfizer have lost 11.7% so far this year compared with the industry’s decrease of 9.7%.
We remind investors that Pfizer added Braftovi to its portfolio with the acquisition of Array BioPharma in 2019. Braftovi is approved in combination with Mektovi (an oral small molecule MEK inhibitor) for the treatment of BRAF-mutant melanoma, the deadliest form of skin cancer.
Braftovi recorded sales worth $48 million in 2019. The label expansion of the drug, is likely to boost its sales in 2020.
Zacks Rank & Other Stocks to Consider
Pfizer currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the large cap pharma sector include AbbVie Inc. ABBV and Bristol-Myers Squibb Company BMY, both holding the same Zacks Rank as Pfizer. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie’s earnings estimates have moved 1.4% north for 2020 and 0.6% north for 2021 over the past 60 days.
Bristol-Myers’ earnings estimates have been revised 6.2% upward for 2020 and 0.5% upward for 2021 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research